Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 5/20 | 0.49 |
| ▸ | GNRHR | P30968 | 11/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6637856 | 0.81 | HTR6 (0.64) | HTR1AHTR6DRD2DRD3HTR7 | |
| SCHEMBL1249685 | 0.79 | HTR6 (0.51) | HTR1AHTR6GNRHRDRD2DRD4 | |
| SCHEMBL10004541 | 0.79 | PARP1 (0.55) | HTR1AHTR6BRD4 | |
| SCHEMBL8687398 | 0.78 | HTR1A (0.49) | HTR1AHTR6GNRHRDRD2DRD4 | |
| SCHEMBL8687723 | 0.76 | DRD4 (0.49) | HTR1AHTR6DRD2DRD4DRD3 | |
| SCHEMBL8687607 | 0.76 | HTR1A (0.48) | HTR1AHTR6GNRHRDRD2DRD4 | |
| SCHEMBL8687612 | 0.75 | HTR6 (0.61) | HTR1AHTR6GNRHRDRD2DRD4 | |
| SCHEMBL23122944 | 0.69 | HTR6 (0.58) | HTR6DRD2DRD3BRD4 | |
| SCHEMBL8136086 | 0.69 | ADRB1 (0.56) | HTR7 | |
| SCHEMBL4889597 | 0.69 | HTR6 (0.60) | HTR6BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063053-B2 | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazoles as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2285784-A1 | 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth LLC (US) | 2011-02-23 | — | — | EP | disclosed |
| WO-2010056644-A1 | 1- (ARYLSULFONYL) -4- (PI PERAZIN-I -YL) -IH-BENZ IMIDAZOLES AS δ-HYDROXYTRYPTAMINE- 6 LIGANDS | WYETH LLC (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100120779-A1 | 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120779-A1 | 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | HTR6, TPH1, HTR4 | HTR1A 6/4885HTR6 1/4885GNRHR 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.